193 related articles for article (PubMed ID: 19759477)
21. A study by means of a new assay of the relationship between an outbreak of erythema infectiosum and non-immune hydrops fetalis caused by human parvovirus B19.
Yaegashi N; Okamura K; Tsunoda A; Nakamura M; Sugamura K; Yajima A
J Infect; 1995 Nov; 31(3):195-200. PubMed ID: 8586838
[TBL] [Abstract][Full Text] [Related]
22. Parvovirus B19 infection in Hong Kong.
Lim WL; Wong KF; Lau CS
J Infect; 1997 Nov; 35(3):247-9. PubMed ID: 9459396
[TBL] [Abstract][Full Text] [Related]
23. Seroepidemiology of parvovirus B19 in the Frankfurt am Main area, Germany: evaluation of risk factors.
Reinheimer C; Allwinn R; Doerr HW; Wittek M
Infection; 2010 Oct; 38(5):381-5. PubMed ID: 20556472
[TBL] [Abstract][Full Text] [Related]
24. Molecular and serological assessment of parvovirus B19 infections among sickle cell anemia patients.
Obeid OE
J Infect Dev Ctries; 2011 Jul; 5(7):535-9. PubMed ID: 21795822
[TBL] [Abstract][Full Text] [Related]
25. The 1994 human parvovirus B19 epidemic in Denmark: diagnostic and epidemiological experience.
Jensen IP; Schou O; Vestergaard BF
APMIS; 1998 Sep; 106(9):843-8. PubMed ID: 9808410
[TBL] [Abstract][Full Text] [Related]
26. Long term follow up of serostatus after maternofetal parvovirus B19 infection.
Dembinski J; Eis-Hübinger AM; Maar J; Schild R; Bartmann P
Arch Dis Child; 2003 Mar; 88(3):219-21. PubMed ID: 12598382
[TBL] [Abstract][Full Text] [Related]
27. Maternal human parvovirus B19 infection and the risk of fetal death and low birthweight: a case-control study within 35 940 pregnant women.
Sarfraz AA; Samuelsen SO; Bruu AL; Jenum PA; Eskild A
BJOG; 2009 Oct; 116(11):1492-8. PubMed ID: 19769750
[TBL] [Abstract][Full Text] [Related]
28. Seroprevalence of parvovirus B19 in blood donors: the risks and challenges of blood transfusion in Zambia in the era of HIV/AIDS at the Kitwe Central Hospital, blood bank.
Chirambo-Kalolekesha M; Kaile T; Mwaba F; Daka V; Simakando M; Kowa S
Afr Health Sci; 2018 Sep; 18(3):496-502. PubMed ID: 30602980
[TBL] [Abstract][Full Text] [Related]
29. Seroprevalence and geographical distribution of parvovirus B19 antibodies in pregnant women: A-meta analysis.
Moosazadeh M; Alimohammadi M; Mousavi T
J Immunoassay Immunochem; 2023 Mar; 44(2):103-116. PubMed ID: 36661768
[TBL] [Abstract][Full Text] [Related]
30. Seroprevalence of parvovirus B19 in fibromyalgia syndrome.
Buyukkose M; Kozanoglu E; Basaran S; Bayramoglu O; Yarkin F
Clin Rheumatol; 2009 Mar; 28(3):305-9. PubMed ID: 19057847
[TBL] [Abstract][Full Text] [Related]
31. Incidence of parvovirus B19 infection among an unselected population of pregnant women in the Netherlands: A prospective study.
van Gessel PH; Gaytant MA; Vossen AC; Galama JM; Ursem NT; Steegers EA; Wildschut HI
Eur J Obstet Gynecol Reprod Biol; 2006; 128(1-2):46-9. PubMed ID: 16406220
[TBL] [Abstract][Full Text] [Related]
32. Human B19 parvovirus infection in an obstetric population. A prospective study determining fetal outcome.
Guidozzi F; Ballot D; Rothberg AD
J Reprod Med; 1994 Jan; 39(1):36-8. PubMed ID: 8169914
[TBL] [Abstract][Full Text] [Related]
33. [Concentration of interleukin-6 and interleukin-12 in pregnant women infected and noninfected with parvovirus B19].
Friedek D; Romanik M; Rogala-Zawada D; Mercik R; Kłuciński P
Wiad Lek; 2001; 54(9-10):492-7. PubMed ID: 11816291
[TBL] [Abstract][Full Text] [Related]
34. Human parvovirus B19 infection during pregnancy--value of modern molecular and serological diagnostics.
Enders M; Schalasta G; Baisch C; Weidner A; Pukkila L; Kaikkonen L; Lankinen H; Hedman L; Söderlund-Venermo M; Hedman K
J Clin Virol; 2006 Apr; 35(4):400-6. PubMed ID: 16332455
[TBL] [Abstract][Full Text] [Related]
35. [Diagnostic and therapy of a severe fetal parvovirus-B19-infection with persistence of viral DNA in the mothers blood but inconspicuous serological tests. Case report].
Stenner S; Enders G; Klee A; Eiden U; Weidner A; Gonser M
Z Geburtshilfe Neonatol; 2002; 206(3):102-6. PubMed ID: 12098826
[TBL] [Abstract][Full Text] [Related]
36. Human parvovirus B19: immunity of Greek females and prenatal investigation of hydrops fetalis.
Kyriazopoulou V; Simitsopoulou M; Bondis J; Diza E; Athanasiadis A; Frantzidou F; Souliou E
Eur J Obstet Gynecol Reprod Biol; 1997 Aug; 74(2):157-60. PubMed ID: 9306109
[TBL] [Abstract][Full Text] [Related]
37. The burden of parvovirus B19 infection in women of childbearing age in England and Wales.
Vyse AJ; Andrews NJ; Hesketh LM; Pebody R
Epidemiol Infect; 2007 Nov; 135(8):1354-62. PubMed ID: 17291377
[TBL] [Abstract][Full Text] [Related]
38. [Antibodies against human parvovirus B19 in the Madrid community].
de Ory F; Pachón I; Ramírez R; Echevarría JM
Enferm Infecc Microbiol Clin; 1999; 17(7):364-5. PubMed ID: 10535193
[No Abstract] [Full Text] [Related]
39. [Analysis of complications during pregnancy in women with serological features of acute toxoplasmosis or acute parvovirosis].
Marcinek P; Nowakowska D; Szaflik K; Spiewak E; Małafiej E; Wilczyński J
Ginekol Pol; 2008 Mar; 79(3):186-91. PubMed ID: 18592853
[TBL] [Abstract][Full Text] [Related]
40. [Infection with parvovirus B19 in pregnant women].
Oszukowski P; Małafiej E; Pertyński T; Szaflik K; Nowak M; Pieta A; Wierzbicka E; Malinowski A
Ginekol Pol; 1996 Mar; 67(3):114-6. PubMed ID: 8647502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
